214 related articles for article (PubMed ID: 36372519)
1. Recent updates on 1,2,3-, 1,2,4-, and 1,3,5-triazine hybrids (2017-present): The anticancer activity, structure-activity relationships, and mechanisms of action.
Dong G; Jiang Y; Zhang F; Zhu F; Liu J; Xu Z
Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200479. PubMed ID: 36372519
[TBL] [Abstract][Full Text] [Related]
2. 1,3,5-Triazine-azole Hybrids and their Anticancer Activity.
Guo H; Diao QP
Curr Top Med Chem; 2020; 20(16):1481-1492. PubMed ID: 32156236
[TBL] [Abstract][Full Text] [Related]
3. Antitumor Activity of s-Triazine Derivatives: A Systematic Review.
Dai Q; Sun Q; Ouyang X; Liu J; Jin L; Liu A; He B; Fan T; Jiang Y
Molecules; 2023 May; 28(11):. PubMed ID: 37298753
[TBL] [Abstract][Full Text] [Related]
4. Moxifloxacin-isatin Hybrids Tethered by 1,2,3-triazole and their Anticancer Activities.
Yang M; Liu H; Zhang Y; Wang X; Xu Z
Curr Top Med Chem; 2020; 20(16):1461-1467. PubMed ID: 31994464
[TBL] [Abstract][Full Text] [Related]
5. Current scenario of pyrazole hybrids with in vivo therapeutic potential against cancers.
Xu Z; Zhuang Y; Chen Q
Eur J Med Chem; 2023 Sep; 257():115495. PubMed ID: 37209450
[TBL] [Abstract][Full Text] [Related]
6. Benzimidazole hybrids as anticancer drugs: An updated review on anticancer properties, structure-activity relationship, and mechanisms of action (2019-2021).
Feng LS; Su WQ; Cheng JB; Xiao T; Li HZ; Chen DA; Zhang ZL
Arch Pharm (Weinheim); 2022 Jun; 355(6):e2200051. PubMed ID: 35385159
[TBL] [Abstract][Full Text] [Related]
7. Recent Updates on the Anticancer Activity of Quinoxaline Hybrids (Jan. 2017-Jan. 2022).
Feng LS; Gao C; Liu FW; Wang XP; Zhang ZL
Curr Top Med Chem; 2022; 22(17):1426-1441. PubMed ID: 36028933
[TBL] [Abstract][Full Text] [Related]
8. 1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Xu Z; Zhao SJ; Liu Y
Eur J Med Chem; 2019 Dec; 183():111700. PubMed ID: 31546197
[TBL] [Abstract][Full Text] [Related]
9.
Dubey P; Pathak DP; Ali F; Chauhan G; Kalaiselvan V
Curr Drug Discov Technol; 2024; 21(2):e170723218813. PubMed ID: 37461340
[TBL] [Abstract][Full Text] [Related]
10. 1,3,5-Triazines: A promising scaffold for anticancer drugs development.
Cascioferro S; Parrino B; Spanò V; Carbone A; Montalbano A; Barraja P; Diana P; Cirrincione G
Eur J Med Chem; 2017 Dec; 142():523-549. PubMed ID: 29046238
[TBL] [Abstract][Full Text] [Related]
11. Coumarin-containing hybrids and their anticancer activities.
Zhang L; Xu Z
Eur J Med Chem; 2019 Nov; 181():111587. PubMed ID: 31404864
[TBL] [Abstract][Full Text] [Related]
12. The current scenario on anticancer activity of artemisinin metal complexes, hybrids, and dimers.
Zhang S; Yi C; Li WW; Luo Y; Wu YZ; Ling HB
Arch Pharm (Weinheim); 2022 Aug; 355(8):e2200086. PubMed ID: 35484335
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in isatin hybrids as potential anticancer agents.
Ding Z; Zhou M; Zeng C
Arch Pharm (Weinheim); 2020 Mar; 353(3):e1900367. PubMed ID: 31960987
[TBL] [Abstract][Full Text] [Related]
14. Artemisinin-derived hybrids and their anticancer activity.
Gao F; Sun Z; Kong F; Xiao J
Eur J Med Chem; 2020 Feb; 188():112044. PubMed ID: 31945642
[TBL] [Abstract][Full Text] [Related]
15. Chalcone hybrids as potential anticancer agents: Current development, mechanism of action, and structure-activity relationship.
Gao F; Huang G; Xiao J
Med Res Rev; 2020 Sep; 40(5):2049-2084. PubMed ID: 32525247
[TBL] [Abstract][Full Text] [Related]
16. Rational design, synthesis and biological screening of triazine-triazolopyrimidine hybrids as multitarget anti-Alzheimer agents.
Jameel E; Meena P; Maqbool M; Kumar J; Ahmed W; Mumtazuddin S; Tiwari M; Hoda N; Jayaram B
Eur J Med Chem; 2017 Aug; 136():36-51. PubMed ID: 28478343
[TBL] [Abstract][Full Text] [Related]
17. Recent advances of podophyllotoxin/epipodophyllotoxin hybrids in anticancer activity, mode of action, and structure-activity relationship: An update (2010-2020).
Xiao J; Gao M; Sun Z; Diao Q; Wang P; Gao F
Eur J Med Chem; 2020 Dec; 208():112830. PubMed ID: 32992133
[TBL] [Abstract][Full Text] [Related]
18. Hydroxamic acid hybrids as the potential anticancer agents: An Overview.
Liu W; Liang Y; Si X
Eur J Med Chem; 2020 Nov; 205():112679. PubMed ID: 32791404
[TBL] [Abstract][Full Text] [Related]
19. Isatin-azole hybrids and their anticancer activities.
Hou Y; Shang C; Wang H; Yun J
Arch Pharm (Weinheim); 2020 Jan; 353(1):e1900272. PubMed ID: 31691360
[TBL] [Abstract][Full Text] [Related]
20. Tetrazole hybrids with potential anticancer activity.
Zhang J; Wang S; Ba Y; Xu Z
Eur J Med Chem; 2019 Sep; 178():341-351. PubMed ID: 31200236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
